PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-06944-y ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Sophie C Kunte und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Positron Emission Tomography Computed Tomography, Receptors, Somatostatin, Thyroid Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Purpose
The novel 18 F-labeled somatostatin receptor (SSTR)-directed radiotracer [ 18 F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [ 18 F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [ 18 F]SiTATE PET/CT in a patient cohort with histologically proven TC.
Methods
As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [ 18 F]SiTATE PET/CT were included (37 scans in total). Mean SUV max and SUV mean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUV max and WB-SUV mean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).
Results
89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUV max 8.6 ± 8.0; SUV mean 5.8 ± 5.4) and nodal (37 lesions; SUV max 8.7 ± 7.8; SUV mean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r 2 = 0.594, p = 0.002). For DTC, no such correlation was present.
Conclusion
Our data demonstrate high feasibility of [ 18 F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [ 18 F]SiTATE may overcome logistical disadvantages of 68 Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
- DIE RADIOLOGIE, Munich, Germany.
- Department of Nuclear Medicine, School of Medicine, Philipps University Marburg, Marburg, Germany.
- Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany.
- Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.
- Research Campus M²OLIE, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.
ORCID-Profile: Adrien Holzgreve
Förderung
- Klinikum der Universität München
Zitieren
APA
Kunte, S. C., Wenter, V., Toms, J., Lindner, S., Unterrainer, M., Eilsberger, F., Jurkschat, K., Wängler, C., Wängler, B., Schirrmacher, R., Tiling, M. W., Sheikh, G. T., Mehrens, D., Brendel, M., Rübenthaler, J., Auernhammer, C. J., Spitzweg, C., Unterrainer, L. M., & Holzgreve, A. (2025). PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06944-y
Vancouver
Kunte SC, Wenter V, Toms J, Lindner S, Unterrainer M, Eilsberger F, et al. PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06944-y
BibTeX
@article{Kunte2025,
author = {Kunte, Sophie C and Wenter, Vera and Toms, Johannes and Lindner, Simon and Unterrainer, Marcus and Eilsberger, Friederike and Jurkschat, Klaus and Wängler, Carmen and Wängler, Björn and Schirrmacher, Ralf and Tiling, Maximilian W and Sheikh, Gabriel T and Mehrens, Dirk and Brendel, Matthias and Rübenthaler, Johannes and Auernhammer, Christoph J and Spitzweg, Christine and Unterrainer, Lena M and Holzgreve, Adrien},
title = {PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-06944-y}
}
EUVIMED